PharmaFocus Today – Page 99 – media

A world first! AstraZeneca “strikes a gold mine”

AstraZeneca recently announced that its PD-L1 monoclonal antibody Imfinzi has been approved by the FDA in the United States for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after concurrent platinum chemotherapy and radiotherapy, becoming the world’s first and only immunotherapy for LS-SCLC. In the ADRIATIC Phase III clinical trial, the average overall survival (OS) of the Imfinzi group was 55.9 months, and that of the placebo group was 33.4 months, a full 22.5 months increase. This is a very groundbreaking progress, breaking the LS-SCLC treatment bottleneck of more than 30 years. AstraZeneca “dug up the gold mine”, and its lung cancer treatment map has been further expanded. Expanding the lung cancer drug map Before 2000, there were only three means of treating lung cancer: chemotherapy, radiotherapy and surgery, especially for patients with advanced lung cancer, who had limited options. It ...
- Source: drugdu
- 249
- December 14, 2024
Wholly-owned Subsidiary’s CS12088 Clinical Trial Application Accepted

According to a news report on December 10, ChipScreen Biotech announced that its wholly-owned subsidiary, Chengdu ChipScreen Pharmaceuticals Co., Ltd., recently received the Acceptance Notice for the clinical trial registration of domestically-produced drugs issued by the National Medical Products Administration (NMPA) Drug Review Center. The clinical trial application for CS12088 has been accepted by the NMPA Drug Review Center. CS12088 is classified as an HBV core assembly modulator, featuring significant antiviral activity, liver-targeting characteristics, and good safety and tolerability. This medication works by interfering with the assembly of the HBV core, blocking the packaging of the viral pre-genomic RNA into the core, which in turn inhibits the replication of HBV DNA and suppresses the production of mature viral particles. The company will actively advance this research and development project and will strictly comply with relevant regulations to timely fulfill its disclosure obligations regarding the subsequent progress of the project. https://finance.eastmoney.com/a/202412103264202237.html
- Source: drugdu
- 151
- December 14, 2024
“Hanquyou” Debuts in the U.S. with First Commercial Supply

Recently, Henlius announced the shipping of its independently developed and produced biosimilar trastuzumab, “Hanquyou,” from the company’s Songjiang base to the U.S. market. This marks the first commercial supply to North America and represents another significant breakthrough in the company’s global strategic layout. With this, Henlius’ commercial supply network has successfully expanded to regions including China, Southeast Asia, North America, Europe, the Middle East, and Latin America. The international market expansion and high-quality development of Henlius are supported by the comprehensive lifecycle services provided by the Songjiang District. Leveraging the Shanghai Biomedical Registration Guidance Service Station, the district has proactively engaged to provide guidance and dedicated tracking, assisting biopharmaceutical companies like Henlius in accelerating drug research and production, which in turn promotes the vigorous development of the strategic emerging industrial cluster in Songjiang’s biopharmaceutical sector. Henlius’s product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmology, with six products ...
- Source: drugdu
- 244
- December 14, 2024
Pharmaceutical companies’ quotations are becoming more “rational”

The selection results of the highly anticipated tenth batch of national drug procurement have been announced. First Finance learned that 62 kinds of drugs were successfully purchased, all of which were out of patent, produced by many enterprises, and fully competitive, covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields; A total of 385 products from 234 companies have obtained the qualification to be selected. According to the selection results released by Shanghai Sunshine Pharmaceutical Procurement Network, although the overall average decrease has not been announced, based on several super large varieties, the price per box (1 box of 100 tablets) of 0.63mg “Compound Alpha Ketonic Acid Tablets” produced by Beijing Fuyuan Pharmaceutical ranges from 149 yuan to 178.99 yuan, with a proposed selection price of 42.82 yuan, a decrease of over 71%; There is also a 10ml specification of “Doxorubicin Hydrochloride Liposome Injection” produced ...
- Source: drugdu
- 174
- December 14, 2024
The foundation of traditional Chinese medicine innovation lies in theoretical innovation

Traditional Chinese medicine is a treasure of Chinese civilization. The Third Plenary Session of the 20th Central Committee of the Communist Party of China explicitly mentioned the need to “improve the mechanism for inheriting, innovating, and developing traditional Chinese medicine.” For enterprises in the field of traditional Chinese medicine, how can they do a good job in the creative transformation and innovative development of traditional Chinese medicine? On December 11th, at the “New Ecology, New Future -2024 China Pharmaceutical and Health Industry Summit Forum” hosted by China Business News, focusing on the inheritance and innovation of traditional Chinese medicine, Wu Rui, the secretary of Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as “Yiling Pharmaceutical”, 002603. SZ), stated that the foundation of traditional Chinese medicine innovation lies in theoretical innovation, which can drive subsequent prescription innovation and production process innovation in the research and development stage. Wu Rui introduced that ...
- Source: drugdu
- 191
- December 14, 2024
Recently, the traditional Chinese medicine industry has been heavily involved in mergers and acquisitions, with multiple companies “crossing boundaries” to layout biochemical innovative drugs

This year, traditional Chinese medicine companies have been intensively involved in mergers and acquisitions. Since August, listed Chinese medicine companies such as Lingrui Pharmaceutical, Kangyuan Pharmaceutical, Pianzaihuang, and CR Sanjiu have announced their merger and acquisition plans. At the same time, the recent establishment of investment funds by Yunnan Baiyao and Pianzaihuang is also considered a prelude to outward mergers and acquisitions. Li Zhong, a senior marketing expert in the pharmaceutical industry, stated in an interview with 21st Century Business Herald that the integration of the entire traditional Chinese medicine industry is inevitable and belongs to the national strategic direction. Large traditional Chinese medicine enterprises may increase their integration efforts, and the industry will present a stronger and stronger force. Traditional Chinese medicine enterprises with well-known brands, good products, good teams, and good research and development will develop rapidly. At the same time, some small enterprises will naturally be integrated, ...
- Source: drugdu
- 231
- December 13, 2024
Anjisheng Biotechnology completes $120 million Series C financing

Reported by WuXi AppTec Content Team On December 11th, Angitia announced the completion of a $120 million Series C funding round led by Bain Capital Life Sciences. The participants in this round of investment include new investor Janus Henderson and existing shareholders Aobo Capital, Sanzheng Health Investment, Yonghua Investment, Junlian Capital, and Lichen Investment. According to the press release, the proceeds from Series C financing will be used to support Anjisheng’s innovative drug pipeline, dedicated to developing differentiated and innovative treatment plans for critical bone, joint, and muscle diseases.Anjisheng Biotechnology is an innovative drug research and development company specializing in the field of severe diseases of bones, joints, and muscles. Currently, three biopolymer candidate drugs are in the clinical research stage, aimed at treating osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Among them, the company is advancing the global clinical development of AGA2118 and AGA2115 for the treatment of osteoporosis ...
- Source: drugdu
- 167
- December 13, 2024
Changes in the order of BTK inhibitors

Over the past decade, the BTK inhibitor market has continued to explode. Since ibrutinib was approved for the treatment of chronic lymphocytic leukemia in 2013, BTK inhibitors have been advancing rapidly, almost dominating the field of hematological tumors, and the market size has exceeded 10 billion US dollars. Of course, with more and more players entering the market, the BTK inhibitor market has also become undercurrent. Ibrutinib is on the decline, and new generation forces such as Calquence, Zebutinib and Pirtobrutinib are on the rise, and more players will enter the market in the future. The emergence of more BTK inhibitors will provide patients with new options for controlling disease progression, but will also bring a new problem: how to combine and how to sort? This still needs pharmaceutical companies to find the answer through exploration. At this year’s ASH Annual Meeting, some pharmaceutical companies brought some new answers to ...
- Source: drugdu
- 207
- December 13, 2024
RSV vaccine clinical trials for infants have been suspended, and safety issues have been foreshadowed

For the increasingly bloated RSV vaccine market, analysts generally conclude that the two RSV vaccines from Pfizer and GSK will dominate the market, while Moderna’s newly launched mRNA vaccine mRNA-1345 (i.e. mResvia) will not occupy much market share this winter due to a variety of reasons such as insufficient commercial preparation. However, now it seems that Moderna may face a worse situation in the future. In the briefing document released by the FDA on December 10, a more unfavorable information for Moderna was revealed: mRNA-1345 and mRNA-1365 may even aggravate RSV virus infection, repeating the mistake of more than 60 years ago that “Pfizer vaccine not only did not alleviate the symptoms of infection, but aggravated the condition of infants and caused death.” Affected by this news, Moderna’s stock price also fell 9% at the close of the market on the 10th. ▍Safety issues that were foreshadowed In July of ...
- Source: drugdu
- 148
- December 13, 2024
The Medical Insurance Bureau named and rectified high-priced Chinese patent medicines

Chinese patent medicines are the concentrated essence of traditional Chinese medicine culture. Compared with Chinese medicine decoctions, they do not need to be decocted and can be used directly. At the same time, they are small in size, easy to carry and store, especially convenient for patients with critical illnesses and patients who need long-term treatment. However, its prices are “ups and downs” and “very different”. Recently, the National Medical Insurance Bureau guided the Hubei Provincial Medical Insurance Bureau to take the lead in carrying out the national alliance procurement of Chinese patent medicines, which will reduce the price of Chinese patent medicines, compress the price difference, and form a more transparent and benign competition market, so that the general public can benefit. ▍What is Chinese patent medicine? Chinese patent medicine is a preparation with certain specifications and dosage forms that can be directly used for the prevention and treatment ...
- Source: drugdu
- 138
- December 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.